By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tikvah Therapeutics 

Atlanta  Georgia    U.S.A.
Phone: Fax:



Start Up

Company News
Tikvah Therapeutics to Present At Lazard Capital Markets Healthcare Conference On November 27 11/16/2007 1:06:23 PM
Tikvah Therapeutics Selected for 'Main-Stage' Presentation At the Ninth Annual Southeastern BIO Investor Forum 11/1/2007 9:28:22 AM
Tikvah Therapeutics and Chakra Biotech Pte. Ltd. Establish Collaboration to Accelerate the Development of Novel Antipsychotic Compounds 9/5/2007 9:37:00 AM
Tikvah Therapeutics Signs Agreement with Phase 2 Discovery, Inc. to Develop and Commercialize LY156735, a Second Generation Melatonin Agonist, for Circadian Rhythm and Sleep Disorders 8/29/2007 7:26:13 AM
FDA Grants Tikvah Therapeutics Orphan Drug Status for Sodium Phenylbutyrate for the Treatment of Spinal Muscular Atrophy 8/20/2007 7:27:19 AM
Tikvah Therapeutics Names Jack W. Callicutt Vice President and Chief Financial Officer 8/9/2007 9:40:18 AM
Tikvah Therapeutics Licenses Unique Solution Formulations Useful in the Treatment of Neurodegenerative Diseases, Including Spinal Muscular Atrophy, From Navinta, LLC 8/7/2007 11:11:48 AM
Tikvah Therapeutics Names Nathan Andrew Shapira, M.D., Ph.D. Executive Director of Clinical Research and Development and Deputy Chief Medical Officer 8/2/2007 9:37:45 AM
Tikvah Therapeutics Licenses Academia Sinica Patent Estate Related to the Diagnosis, Method of Use, and Treatment of Neurodegenerative Diseases Including Spinal Muscular Atrophy 7/24/2007 8:45:56 AM
Tikvah Therapeutics Enters an Exclusive Licensing Agreement With Apkarian Technologies Related to Agents for Treatment of Pain and Pain-Related Indications 7/16/2007 11:59:52 AM